1HARDING M W. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy[J]. Clin Cancer Res, 2003, 9:2882 - 2886. 被引量：1
2PANTUCK A J, ZENG G, BELLDEGRUN A S, et al. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway [J]. Clin Cancer Res, 2003, 9:4641 - 4652. 被引量：1
3MILLS G B, LU Y L, KOHN E C. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the P13K pathway preferentially blocks PTEN mutant cells in vitro and in vivo [J]. Proc Natl Acad Sci USA, 2001, 98(18) : 10031 - 10033. 被引量：1
4HUDES G, CARDUCCI M, TOMCZAK P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. New Engl J Med, 2007, 356(22) :2271 - 2281. 被引量：1
同被引文献9
1Hudes G,Carducci M,Tomczak P. Temsirolimus,interferon alfa,or both for advanced renal-cell carcinoma[J].{H}New England Journal of Medicine,2007,(22):2271-2281. 被引量：1
2Sorbera L A,Castaner J,Del Fresno M. CCI-799:Oncolytic mTOR inhibitor[J].{H}Drugs of the Future,2002,(1):7-13. 被引量：1
3Gu J X,Ruppen M E,Cai P. Lipase-catalyzed regioselective esterification of rapamycin:synthesis of Temsirolimus (CCI-779)[J].{H}Organic Letters,2005,(18):3945-3948. 被引量：1
